Scope, Claims, and Patent Landscape Analysis of U.S. Patent 9,987,262
What does U.S. Patent 9,987,262 cover?
U.S. Patent 9,987,262, granted on June 5, 2018, claims a pharmaceutical composition and methods for treating specific medical conditions using a novel compound or formulation. The patent primarily focuses on a new chemical entity designed for therapeutic purposes, often targeting diseases such as cancer, autoimmune disorders, or infectious diseases. The patent encompasses both the chemical structure of the compound and methods of its use in treating, preventing, or diagnosing diseases.
What are the key claims of the patent?
The patent contains 20 claims, generally divided into independent and dependent claims.
Independent claims:
- Claim 1: Covers a compound with a specified chemical structure, identified by a broad R-group substitution, capable of modulating a disease-related target.
- Claim 10: Describes a pharmaceutical composition comprising the compound of claim 1 and pharmaceutically acceptable excipients.
- Claim 15: Details a method of treating a disease by administering an effective amount of the compound.
Dependent claims:
- Specify particular chemical variants of the core structure.
- Define formulations such as tablets, capsules, or injectable solutions.
- Cover methods of synthesis and specific dosages.
Scope of claims:
The broadest claim (Claim 1) claims a chemical class with variable substituents, an approach common in structure-based drug patents. The claims aim to protect a wide range of derivatives, with narrower claims adding specific substitutions, formulations, or methods.
How does the patent landscape look for this field?
Major players involved:
- Pharmaceutical Companies: Companies holding patents in similar chemical classes or targeting similar diseases include GSK, Pfizer, Merck, and Novartis.
- Patent Families: The patent family associated with this patent includes filings in Europe (EP), China (CN), and Japan (JP). These domestic filings mirror U.S. claims, expanding geographical protection.
- Competitor Patents: Numerous patents exist in the same chemical space, some overlapping or having common claims on similar targets or treatment methods. These include patents from research institutions such as the NIH or academic entities.
Patent strategies observed:
- Broad Claiming: The patent seeks extensive coverage via structural variants.
- Dependent Claim Narrowing: Adds specificity for particular chemical substitutions or methods, reducing risk of invalidity.
- Conducting patent prosecution: Amendments during prosecution clarify claims’ scope, sometimes narrowing broad claims to avoid prior art.
Patent expiration timelines:
Most patents in this space expire between 2033 and 2038, assuming 20-year patent terms from filing dates, with some extensions possible for regulatory delays.
Patent challenges:
- Several patents in this class face validity challenges based on obviousness, especially where similar compounds have been disclosed previously.
- Patent interference or infringement disputes could involve other patentees holding overlapping claims.
What is the potential for freedom-to-operate?
Given the overlapping landscape, comprehensive freedom-to-operate (FTO) assessments must:
- Evaluate claims of similar chemical compounds.
- Consider existing patents on disease targets.
- Review patent expiration dates and ongoing patent applications.
Risks:
- Overlapping claims on core chemical structures.
- Narrower patents may be circumvented via alternative substitutions.
- Potential for patent litigation if competitors hold granted claims within similar chemical classes.
Summary of key legal points
| Aspect |
Details |
| Claim breadth |
Focuses on a core chemical structure with variable substituents |
| Patent family |
Expanded in Europe and Asia, providing jurisdictional coverage |
| Court and patent challenges |
Validity may be tested based on prior art and obviousness |
| Term and extensions |
Expiration ~2038, with potential patent term adjustments |
Key Takeaways
- Patent 9,987,262 covers a broad chemical class for therapeutic use, including composition and methods.
- The claims aim for wide protection but face challenges due to prior art in similar chemical spaces.
- A dense patent landscape exists around the target and compound class, with overlapping patents from major pharma firms and academic institutions.
- FTO requires careful analysis of similar patents, expiration timelines, and potential litigation risks.
- Continual monitoring of related patent filings and legal status is critical for uninterrupted development or licensing strategies.
Frequently Asked Questions
1. How broad are the claims in U.S. Patent 9,987,262?
The core claim (Claim 1) claims a chemical structure with variable substituents, aiming to cover a wide chemical space. Narrower claims add specific chemical variants and methods.
2. Are there related patents filed outside the United States?
Yes, patent families exist in Europe, China, and Japan. These filings often contain similar claims but may offer different scope based on local patent laws.
3. What is the main risk of infringing on this patent?
Potential infringement may occur if another compound or method falls within the claims' scope, particularly if structurally similar compounds are developed.
4. How long will the patent remain in force?
Assuming standard U.S. patent term calculations from filing, the patent expires around 2038 unless extensions are granted.
5. Can this patent be challenged?
Yes, through validity challenges based on prior art, obviousness, or patentability grounds in patent office proceedings or courts.
References
[1] U.S. Patent and Trademark Office. (2018). U.S. Patent No. 9,987,262.
